Table 1 Background characteristics of the patient, overall and by CnLN examination status (N = 1178)
Variable | CnLN examined | P value | ||
|---|---|---|---|---|
All patients (N = 1178) | Positive (N = 342) | Negative (N = 836) | ||
Age, average, years | 58.54 (7–84) | 58.39 (23–81) | 58.60 (7–81) | 0.258 |
< 60, N(%) | 582 (49.4%) | 169 (49.4%) | 413 (49.4%) | 0.997 |
≥ 60, N(%) | 596 (50.6%) | 173 (50.6%) | 423 (50.6%) | |
Gender, N (%) | ||||
Female | 337 (28.6%) | 98 (28.7%) | 239 (28.6%) | 0.517 |
Male | 841 (71.4%) | 244 (71.3%) | 597 (71.4%) | |
Diagnosed year | ||||
2004–2006 | 185 (15.7%) | 61 (17.8%) | 124 (14.8%) | 0.245 |
2007–2009 | 359 (30.5%) | 109 (31.9%) | 250 (29.9%) | |
2010–2012 | 634 (53.8%) | 172 (50.3%) | 462 (55.3%) | |
Tumor size | ||||
≤ 4 cm | 480 (40.7%) | 105 (30.7%) | 375 (44.9%) | < 0.001 |
> 4 cm | 698 (59.3%) | 237 (69.3%) | 461 (55.1%) | |
Number of examined LN, average | 22.74 (3–119) | 25.70 (4–119) | 21.53 (3–82) | 0.174 |
Number of positive LN, average | 6.01 (1–118) | 12.20 (1–118) | 3.47 (3–79) | < 0.001 |
Type of resection | ||||
Total gastrectomy | 202 (17.1%) | 63 (18.4%) | 139 (16.6%) | 0.254 |
Subtotal gastrectomy | 976 (82.9%) | 279 (81.6%) | 697 (83.4%) | |
Location | ||||
Antrum/pylorus | 620 (52.6%) | 183 (53.5%) | 437 (52.3%) | 0.428 |
Body/fundus | 124 (10.5%) | 32 (9.4%) | 92 (11.0%) | |
GEJ/cardia | 152 (12.9%) | 38 (11.1%) | 114 (13.6%) | |
Total | 282 (23.9%) | 89 (26.0%) | 193 (23.1%) | |
Histology grade | ||||
Differentiated | 441 (37.4%) | 111 (32.5%) | 330 (39.5%) | 0.014 |
Un-differentiated | 737 (62.6%) | 231 (67.5%) | 506 (60.5%) | |
Signet ring cell | ||||
Yes | 119 (10.1%) | 48 (14.0%) | 71 (8.5%) | 0.004 |
No | 1059 (89.9%) | 294 (86.0%) | 765 (91.5%) | |
Lymphatic vessel invasion | ||||
Yes | 280 (23.8%) | 128 (37.4%) | 152 (18.2%) | < 0.001 |
No | 898 (76.2%) | 214 (62.6%) | 684 (81.8%) | |
Pathological T stage | ||||
T2 | 220 (18.7%) | 41 (12.0%) | 179 (21.4%) | < 0.001 |
T3 | 666 (56.5%) | 194 (56.7%) | 472 (56.5%) | |
T4 | 292 (24.8%) | 107 (31.3%) | 185 (22.1%) | |
Pathological N stage | ||||
N0 | 323 (27.4%) | 0 (0.0%) | 323 (38.6%) | < 0.001 |
N1 | 219 (18.6%) | 35 (10.2%) | 184 (22.0%) | |
N2 | 265 (22.5%) | 84 (24.6%) | 181 (21.7%) | |
N3 | 371 (31.5%) | 223 (65.2%) | 148 (17.7%) | |